# OnCo record advanced-stage-classical-hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "advanced-stage-classical-hodgkin-lymphoma" ;
  schema:name "Advanced-stage classical Hodgkin lymphoma (stage III to IV)"@en ;
  schema:alternateName "Stage III to IV classical Hodgkin lymphoma"@en, "Advanced Hodgkin lymphoma"@en, "Disseminated Hodgkin lymphoma"@en, "High-risk Hodgkin lymphoma (IPS 4 or more)"@en ;
  schema:description "Advanced-stage classical Hodgkin lymphoma is Hodgkin lymphoma involving nodes on both sides of the diaphragm or organs such as the liver, lungs or bone marrow. It is treated with six cycles of combination chemotherapy, and two trials changed the standard: replacing bleomycin with brentuximab vedotin (ECHELON-1) and then with nivolumab (SWOG S1826), which cured more patients with less toxicity."@en ;
  schema:url <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2405888>, <https://doi.org/10.1056/NEJMoa1708984>, <https://doi.org/10.1016/S0140-6736(24)01315-1>, <https://en.wikipedia.org/wiki/Hodgkin_lymphoma>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/types-lymphoma/hodgkin-lymphoma/classical-hodgkin-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment>, <https://doi.org/10.1056/NEJMoa1510093>, <https://doi.org/10.1016/S0140-6736(24)01315-1>, <https://doi.org/10.1200/JCO.2012.44.3721>, <https://www.nhs.uk/conditions/hodgkin-lymphoma/treatment/> ;
  onco:tag "subtype-page", "haematologic" ;
  onco:related <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/g-csf-growth-factors/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/pet-ct/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/reed-sternberg-cell/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-beacopp-or-abvd/>, <https://onco.cc/terms/lymphoma-decision-fertility-timing/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/terms/deauville/> ;
  onco:trials <https://onco.cc/trials/echelon-1/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/trials/nct02979522/>, <https://onco.cc/trials/hd18/>, <https://onco.cc/trials/ahl2011/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/>, <https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/>, <https://onco.cc/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/>, <https://onco.cc/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/> ;
  onco:pipeline <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/nct02979522/>, <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/ideas/idea-chemo-free-hodgkin/> ;
  onco:standardOfCare <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/trials/echelon-1/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/pairings/bleomycin-omission-caution/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/trials/nct02979522/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/trials/echelon-1/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/technologies/g-csf-growth-factors/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/>, <https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/> .